Skip to content
ATLAS PREP HQ
Growth Hormone

Sermorelin

GHRH(1–29)NH2, the bioactive N-terminal fragment of human growth hormone-releasing hormone

GHRH-analog research intended to stimulate endogenous, physiologic growth-hormone release.

Limited Human Evidence

Route

Subcutaneous.

Common format

5 mg vial

Research focus

GH deficiency physiology

Evidence level

Limited Human Evidence

Typical cycle

3–6 months

Growth Hormone research motifGrowth Hormone

Sermorelin in 30 seconds

Atlas Fast Read

What it is

GHRH(1–29)NH2, the bioactive N-terminal fragment of human growth hormone-releasing hormone

Why people care

GHRH-analog research intended to stimulate endogenous, physiologic growth-hormone release.

Human evidence

Limited Human Evidence — Human interventional or clinical data exist, but studies are small, early-phase, mixed, indirect, route-specific, or not confirmatory.

Biggest misconception

Key gaps include larger independent trials, clearer dose-response data, long-term safety, clinically meaningful endpoints, and evidence that findings generalize beyond the narrow populations or routes already studied.

Bottom line

Sermorelin has a real human signal or documented human pharmacology, but evidence is too small, mixed, route-specific, or indication-specific to justify broad claims.

Overview

What is Sermorelin?

Sermorelin is gHRH(1–29)NH2, the bioactive N-terminal fragment of human growth hormone-releasing hormone. GHRH-analog research intended to stimulate endogenous, physiologic growth-hormone release.

Sermorelin was developed as the bioactive 1–29 fragment of GHRH and was historically approved in the United States for pediatric GH-related diagnostic/treatment use before the branded product was discontinued.

Mechanism

How it works

Binds pituitary GHRH receptors, stimulating endogenous pulsatile GH release and downstream hepatic/peripheral IGF-1 while retaining physiologic negative feedback.

Research areas

GH deficiency physiologyGH stimulationIGF-1sleep/body-composition research

Evidence

What does the evidence actually say?

Limited Human Evidence

Human interventional or clinical data exist, but studies are small, early-phase, mixed, indirect, route-specific, or not confirmatory.

01

Preclinical Evidence

02

Limited Human Evidence

03

Strong Human Evidence

Human evidence

Human studies establish that sermorelin can stimulate endogenous GH release, and it has a historical FDA-approved pediatric/diagnostic background. Evidence for modern adult anti-aging, physique, or wellness protocols is limited.

Preclinical evidence

Preclinical and human physiology both confirm GHRH-receptor stimulation of endogenous GH. Uncertainty concerns adult wellness outcomes rather than the core endocrine mechanism.

Knowledge gaps

Key gaps include larger independent trials, clearer dose-response data, long-term safety, clinically meaningful endpoints, and evidence that findings generalize beyond the narrow populations or routes already studied.

Protocol

Research protocol

DoseFrequencyTimingCycle

Dose

community sources adult research reference: 200–500 mcg nightly. Historical pediatric dosing and diagnostic use were weight-based and should not be conflated with wellness protocols.

Frequency

Once daily.

Timing

Bedtime in the community protocol to align with nocturnal GH physiology.

Route

Subcutaneous.

Cycle length

3–6 months

Reconstitution

Community reference: 0.5 mL bacteriostatic water per 5 mg vial = 10 mg/mL.

Storage

Community reference: lyophilized refrigerated; reconstituted 2–8 °C and use within about 10–14 days.

Monitoring

IGF-1, fasting glucose/HbA1c, thyroid function when clinically indicated, edema/arthralgia and symptoms suggesting pituitary disease.

Protocols vary widely between sources. Investigational compounds are not approved therapies, and approved products should follow their official labeling. Nothing here is medical advice.

Safety

Safety, side effects, and precautions

Side effects

Potential GH/IGF-axis effects include edema, joint pain, tingling/carpal-tunnel-like symptoms, headache, flushing, increased appetite in some secretagogues, and worsening glucose tolerance. Injection-site reactions can occur.

Contraindications

Avoid in active malignancy and use extreme caution with uncontrolled diabetes, proliferative retinopathy, untreated pituitary disease, pregnancy/breastfeeding or significant edema. Exact contraindications are not established for research formulations.

Interactions

GH/IGF signaling can alter glucose control, so insulin and other glucose-lowering therapy may require closer monitoring. Glucocorticoids can blunt GH effects; thyroid status can influence response. Formal interaction data are limited for research secretagogues.

Stacks

Common stacks

No well-supported stack is highlighted for this peptide yet.

Questions

FAQ

References

Sources

Atlas

The Atlas verdict

Sermorelin has a real human signal or documented human pharmacology, but evidence is too small, mixed, route-specific, or indication-specific to justify broad claims. The most defensible use of the literature is to separate what has actually been measured in people from what is still extrapolated from mechanism or animal work.

More in Growth Hormone

Growth Hormone

CJC-1295 DAC

Long-acting GHRH analog research designed to extend growth-hormone signaling over multiple days.

Read guide

Growth Hormone

CJC-1295 NO DAC + Ipamorelin

GHRH plus growth-hormone secretagogue research intended to support more pulsatile GH release.

Read guide

Growth Hormone

GHRP-2

Ghrelin-receptor agonist research focused on stimulating growth-hormone secretion.

Read guide